global top 14 companies accounted for 86% of total Covid-19 Treatment market(qyresearch, 2021) | |
Patients today have more treatment options in the battle against coronavirus disease. In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms. The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care. The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc. According to the new market research report “United States Covid-19 Treatment Market Report 2023-2029”, published by QYResearch, the United States Covid-19 Treatment market size is projected to reach USD 0.05 billion by 2029, at a CAGR of -50.7% during the forecast period. The United States key manufacturers of Covid-19 Treatment include Zhejiang Hisun Pharmaceutical Co. Ltd, ImmunoPrecise, Pharmstandard, Fujifilm Holdings, Cipla, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi, GlaxoSmithKline, Cipla, etc. In 2021, the United States top five players had a share approximately 86.0% in terms of revenue. For more information, please contact the following e-mail address: Email: global@qyresearch.com Website: https://www.qyresearch.com | |
Target Nation: All Nations Target City : All Cities Last Update : 28 April 2024 4:19 AM Number of Views: 98 | Item Owner : Ann Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |